Quintiles Transnational Holdings Inc. — Q1 2013 Form 10-Q
Filing identity: The supplied filing is for Quintiles Transnational Holdings Inc., not IQVIA Holdings Inc. It covers the three months ended March 31, 2013; financial statements are unaudited. Amounts below are U.S. dollars.
Business context and results
Quintiles provided biopharmaceutical development and commercial outsourcing services through Product Development and Integrated Healthcare Services, operating in approximately 100 countries with about 27,000 employees.
| Metric | Q1 2013 | Q1 2012 | Change |
|---|---|---|---|
| Service revenues | $927.4 million | $888.0 million | +4.4% |
| Total revenues, including reimbursed expenses | $1,228.8 million | $1,156.6 million | +6.2% |
| Operating income | $115.2 million | $92.0 million | +25.2% |
| Net income attributable to Quintiles | $48.3 million | $43.3 million | +11.6% |
| Diluted EPS | $0.41 | $0.37 | +$0.04 |
| Operating cash flow | $(21.5) million | $4.6 million | Down $26.1 million |
Service-revenue growth was approximately 5.7% at constant currency; foreign exchange reduced reported growth by about $16.5 million. Operating margin was approximately 12.4% of service revenues, versus 10.4% a year earlier. The effective tax rate was 39.2%, up from 37.0%. Interest expense rose to $36.0 million from $29.3 million, primarily reflecting additional term loans.
Segments and material changes
- Product Development: service revenues rose 7.6% to $706.3 million; segment operating income increased 18.5% to $132.7 million, with margin improving to 18.8% from 17.1%. Growth reflected higher clinical-services volume and backlog delivery.
- Integrated Healthcare Services: service revenues fell 4.6% to $221.1 million and operating income declined 56.6% to $6.2 million; margin fell to 2.8% from 6.2%. The filing cites currency impacts, contract completions or scope reductions, and a shift toward lower-margin Italian product distribution revenue.
- Backlog was $9.0 billion at quarter-end, compared with $8.7 billion at year-end 2012. Net new business was $1.2 billion, up 18% year over year, driven by Product Development; Integrated Healthcare Services bookings declined.
- SG&A decreased $6.5 million, partly because Q1 2012 included option-repricing compensation and a bonus that did not recur. Restructuring costs were $1.9 million in Q1 2013, versus a $0.3 million net credit in Q1 2012.
Cash, debt, liquidity, and outlook
Cash and cash equivalents were $454.3 million at March 31, 2013, down from $567.7 million at December 31, 2012; $89.6 million was held in the United States. Current assets were $1.44 billion and current liabilities $1.22 billion. Balance-sheet debt and capital-lease obligations totaled approximately $2.39 billion, including $34.7 million current; management separately reported total indebtedness of $2.41 billion, excluding $300 million available under the revolving facility. Shareholders’ deficit was $1.32 billion. Operating cash use, investing cash use of $36.2 million, financing cash use of $34.0 million, and $21.8 million of adverse currency effects contributed to the quarterly cash decline.
Management said available cash, expected IPO proceeds, operating cash flows, and revolving-credit access should cover operating needs, capital expenditures, and debt obligations for at least 12 months. The filing described an expected May 2013 IPO: approximately $489.8 million in net proceeds to the company, with intended uses including repayment of approximately $306 million of the Holdings Term Loan, $50 million of secured-facility debt, a $25 million management-agreement termination fee, and general corporate purposes. Selling-shareholder proceeds would not go to the company. These were forward-looking expectations in the filing, not Q1 operating results.
A 2013 restructuring plan authorized up to $15 million of costs, expected to affect about 400 positions; management estimated annual savings of $15–$20 million. The company hedged interest-rate exposure on approximately $975 million of variable-rate borrowings, about 46.2% of the relevant debt, and had $32.1 million of unrealized swap losses. Management cautioned that contracts may be terminated on short notice, backlog does not assure future revenue timing, and customer, regulatory, execution, foreign-exchange, and substantial-debt risks could affect results. No significant risk-factor changes or material changes in market-risk disclosures were reported; management said disclosure controls were effective.
Important facts for investors to verify
- Confirm the issuer and period: this source is Quintiles Transnational Holdings Inc.’s Q1 2013 filing, despite the IQVIA metadata.
- Check subsequent IPO completion, actual net proceeds, and debt repayments against the estimates disclosed after quarter-end.
- Track operating cash conversion, receivables and unbilled services, and whether the Q1 working-capital cash outflow reversed.
- Assess whether Product Development growth and Integrated Healthcare Services’ margin pressure persisted, and whether backlog converted to revenue as expected.
- Monitor debt, covenant compliance, restructuring charges and realized savings, and exposure to foreign exchange and interest rates.